Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.71 Billion INR | -17.04% |
| 2022 | 12.91 Billion INR | 63.17% |
| 2021 | 7.91 Billion INR | 1.04% |
| 2020 | 7.83 Billion INR | 8.79% |
| 2019 | 7.19 Billion INR | 59.62% |
| 2018 | 4.5 Billion INR | 10.74% |
| 2017 | 4.07 Billion INR | 59.68% |
| 2016 | 2.55 Billion INR | -17.57% |
| 2015 | 3.09 Billion INR | 1.35% |
| 2014 | 3.05 Billion INR | -14.26% |
| 2013 | 3.56 Billion INR | 9.51% |
| 2012 | 3.25 Billion INR | -7.32% |
| 2011 | 3.5 Billion INR | 19.58% |
| 2010 | 2.93 Billion INR | -5.43% |
| 2009 | 3.1 Billion INR | 1.44% |
| 2008 | 3.05 Billion INR | 36.04% |
| 2007 | 2.24 Billion INR | 47.15% |
| 2006 | 1.52 Billion INR | 15.49% |
| 2005 | 1.32 Billion INR | 11.06% |
| 2004 | 1.19 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -35.67 Billion INR | -433.08% |
| 2024 Q2 | 11.13 Billion INR | 131.21% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 10.71 Billion INR | -17.04% |
| 2023 Q4 | 10.71 Billion INR | 0.0% |
| 2023 Q2 | 9.51 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 8.44 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 12.91 Billion INR | 63.17% |
| 2022 Q4 | 12.91 Billion INR | 0.0% |
| 2021 Q4 | 7.91 Billion INR | 0.0% |
| 2021 FY | 7.91 Billion INR | 1.04% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 7.04 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 7.83 Billion INR | 0.0% |
| 2020 FY | 7.83 Billion INR | 8.79% |
| 2020 Q2 | 7.57 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 FY | 7.19 Billion INR | 59.62% |
| 2019 Q4 | 7.19 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 6.23 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 4.58 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 4.5 Billion INR | 10.74% |
| 2018 Q4 | 4.5 Billion INR | 0.0% |
| 2017 FY | 4.07 Billion INR | 59.68% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 3.36 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 4.07 Billion INR | 0.0% |
| 2016 Q4 | 2.55 Billion INR | 0.0% |
| 2016 FY | 2.55 Billion INR | -17.57% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 2.88 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 3.09 Billion INR | 1.35% |
| 2015 Q4 | 3.09 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 2.81 Billion INR | 0.0% |
| 2014 FY | 3.05 Billion INR | -14.26% |
| 2014 Q4 | 3.05 Billion INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 3.56 Billion INR | 9.51% |
| 2012 FY | 3.25 Billion INR | -7.32% |
| 2011 FY | 3.5 Billion INR | 19.58% |
| 2010 FY | 2.93 Billion INR | -5.43% |
| 2009 FY | 3.1 Billion INR | 1.44% |
| 2008 FY | 3.05 Billion INR | 36.04% |
| 2007 FY | 2.24 Billion INR | 47.15% |
| 2006 FY | 1.52 Billion INR | 15.49% |
| 2005 FY | 1.32 Billion INR | 11.06% |
| 2004 FY | 1.19 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 34.187% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 92.963% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -106.727% |
| Granules India Limited | 22.95 Billion INR | 53.341% |
| Indoco Remedies Limited | 10.34 Billion INR | -3.558% |
| Achyut Healthcare Limited | 2.01 Million INR | -531956.632% |
| Alkem Laboratories Limited | 48.6 Billion INR | 77.965% |
| Alpa Laboratories Limited | 307.12 Million INR | -3387.311% |
| Brooks Laboratories Limited | 248.6 Million INR | -4208.229% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -192.543% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -120.029% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -407.874% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 89.987% |
| Eris Lifesciences Limited | 38.26 Billion INR | 72.012% |
| FDC Limited | 3.7 Billion INR | -188.749% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 83.551% |
| Gufic Biosciences Limited | 5.59 Billion INR | -91.262% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -367.809% |
| Ipca Laboratories Limited | 33.74 Billion INR | 68.259% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -3509.078% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -260.142% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1876.344% |
| Laurus Labs Limited | 42.71 Billion INR | 74.926% |
| Lupin Limited | 96.23 Billion INR | 88.871% |
| Mankind Pharma Limited | 23.87 Billion INR | 55.139% |
| Medicamen Biotech Limited | 940.36 Million INR | -1038.949% |
| Medico Remedies Limited | 438.24 Million INR | -2343.913% |
| Megasoft Limited | 1.85 Billion INR | -477.953% |
| NATCO Pharma Limited | 10.53 Billion INR | -1.693% |
| Piramal Pharma Limited | 74 Billion INR | 85.527% |
| RPG Life Sciences Limited | 1.38 Billion INR | -675.996% |
| Sigachi Industries Limited | 2.53 Billion INR | -323.12% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 94.166% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -426.504% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -819.173% |
| Unichem Laboratories Limited | 8.06 Billion INR | -32.73% |
| Wanbury Limited | 3.15 Billion INR | -239.415% |
| Windlas Biotech Limited | 1.76 Billion INR | -507.608% |
| ZIM Laboratories Limited | 2.08 Billion INR | -414.73% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 85.081% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -175.124% |
| Divi's Laboratories Limited | 18.99 Billion INR | 43.6% |
| Hester Biosciences Limited | 3.59 Billion INR | -197.945% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -318.175% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1266.416% |
| Bal Pharma Limited | 2.51 Billion INR | -326.488% |
| Strides Pharma Science Limited | 37.68 Billion INR | 71.576% |
| Venus Remedies Limited | 1.39 Billion INR | -668.976% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -29.811% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 4.526% |
| Shilpa Medicare Limited | 12.93 Billion INR | 17.183% |
| Aarti Drugs Limited | 11.5 Billion INR | 6.899% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -69.228% |
| Suven Life Sciences Limited | 148.62 Million INR | -7106.451% |
| Ind-Swift Limited | 13.45 Billion INR | 20.387% |
| Valiant Laboratories Limited | 1.05 Billion INR | -912.068% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -0.021% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 24.276% |
| Themis Medicare Limited | 1.88 Billion INR | -467.43% |
| Hikal Limited | 12.99 Billion INR | 17.581% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 86.947% |
| Sequent Scientific Limited | 8.27 Billion INR | -29.441% |
| Novartis India Limited | 1.8 Billion INR | -494.653% |
| Wockhardt Limited | 39.87 Billion INR | 73.137% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 82.521% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -3608.565% |
| Neuland Laboratories Limited | 5.49 Billion INR | -94.784% |
| Morepen Laboratories Limited | 4.45 Billion INR | -140.153% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1563.392% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -441.934% |